CD274 and non-small cell lung carcinoma: The KEYNOTE‐010 study,2 primarily aiming to reveal the overall survival and progression‐free survival rates of pembrolizumab monotherapy for previously treated patients with NSCLC with PD‐L1 expression ≥1%, reported a rate of 10.4% for severe adverse events.